Ascendis Pharma (ASND) Moves 17.1% Higher: Will This Strength Last?Zacks Investment Research • 09/17/24
Ascendis Pharma's Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next YearBenzinga • 09/16/24
Ascendis Rockets — And Hammers BioMarin — On New Results For Growth DrugInvestors Business Daily • 09/16/24
Pivotal ApproaCH Trial of TransCon™ CNP (Navepegritide) Achieved Primary Objective, Demonstrated AGV Superior to PlaceboGlobeNewsWire • 09/16/24
Ascendis to Present First Results from Platinum-Resistant Ovarian Cancer (PROC) Cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024GlobeNewsWire • 09/13/24
Ascendis Pharma Receives Orphan Drug Exclusivity in the U.S. for YORVIPATH® (Palopegteriparatide) for the Treatment of Hypoparathyroidism in AdultsGlobeNewsWire • 09/11/24
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh InBenzinga • 09/04/24
Ascendis Pharma Undercuts 50-Day Line After Pricing Fiasco Prompts Guidance CutInvestors Business Daily • 09/04/24
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance CutBenzinga • 09/04/24
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding AgreementGlobeNewsWire • 09/03/24
Ascendis Pharma to Report Second Quarter 2024 Financial Results and Provide Business Update on September 3, 2024GlobeNewsWire • 08/28/24
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains?Zacks Investment Research • 08/14/24
Ascendis Pharma: Yorvipath Approved, Launch Delayed, Many Other Updates Coming UpSeeking Alpha • 08/13/24
Ascendis Pharma Zips Higher After FDA Approves Embattled Thyroid DrugInvestors Business Daily • 08/12/24
Ascendis Pharma's stock surges after FDA approval for first and only treatment for rare diseaseMarket Watch • 08/12/24
Weaker USD, Revenue Growth, And TransCon Technology Make Ascendis Pharma A Strong Buy OpportunitySeeking Alpha • 07/29/24
Data from Phase 2 ACcomplisH Trial of TransCon CNP in Children with Achondroplasia Presented at ICCHBH 2024GlobeNewsWire • 06/24/24
Ascendis Pharma to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/04/24
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024GlobeNewsWire • 06/03/24